MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.90
-0.10
-0.34%
After Hours: 27.93 +0.03 +0.12% 16:12 07/10 EDT
OPEN
28.02
PREV CLOSE
28.00
HIGH
28.29
LOW
27.80
VOLUME
691.60K
TURNOVER
--
52 WEEK HIGH
29.34
52 WEEK LOW
12.71
MARKET CAP
3.79B
P/E (TTM)
-49.8036
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HALO stock price target is 30.00 with a high estimate of 39.00 and a low estimate of 13.00.

EPS

HALO News

More
Drug Stock May Be Overdue for a Short Squeeze
Schaeffer's Investment Research · 2d ago
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 4d ago
Value stocks with momentum may offer opportunity amid stretched valuations
Seeking Alpha - Article · 5d ago
Value, momentum stock hybrids in focus amid stretched valuations
Seeking Alpha - Article · 5d ago
Piper Sandler Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $31
Piper Sandler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $28 to $31.
Benzinga · 07/02 13:40
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21
Edited Transcript of HALO.OQ earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 Halozyme Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 07/01 23:20
Benchmark Initiates Coverage On Halozyme Therapeutics with Buy Rating, Announces Price Target of $39
Benchmark analyst Robert Wasserman initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Buy rating and announces Price Target of $39.
Benzinga · 07/01 12:26

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About HALO

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
More

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.